title: Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats.
abstract: The angiotensin AT1 receptor antagonists, losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'(1H-tetrazol-5-yl)biphen yl-4- yl)methyl]imidazole potassium salt), EXP3174 (2-n-butyl-4-chloro-1-[(2'(1 H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid), GR117289 (1-[[3-bromo-2-[2-(1 H-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-2-butyl-4-chloro-1 H-imidazole-5-carboxylic acid) and LR-B/081 (methyl-2-[[4-butyl-2-methyl-6-oxo-5-[[2'-(1 H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1(6H)-pyrimidinyl]met hyl]-3- thiophenecarboxylate), given by intraperitoneal (i.p.) injection 15 min before intracerebroventricular administration of angiotensin II, inhibited drinking with the following order of potency: EXP3174 > GR117289 > losartan > LR-B/081. When 20 mumol/kg of each antagonist was i.p. injected 15 min, 4, 12 or 24 h before angiotensin II, EXP3174 and GR117289 inhibited water intake at each observation time, losartan at 4, 12 and 24 h, LR-B/081 only at 4 and 12 h. After per os administration of the same dose 4 or 12 h before angiotensin II, losartan reduced drinking at 4, but not at 12 h; LR-B/081 did not inhibit drinking either at 4 or 12 h. The present results suggest that EXP3174 and GR117289 cross the barrier readily. The effect of i.p. losartan on central angiotensin mechanisms is not prompt, suggesting that it may require conversion to EXP3174. LR-B/081 apparently crosses the barrier less readily than the other antagonists following both i.p. and per os administration.
authors.affiliation: Institute of Pharmacology, University of Camerino, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Polidori
authors.forename: R
authors.initials: R
authors.lastname: Ciccocioppo
authors.forename: P
authors.initials: P
authors.lastname: Pompei
authors.forename: R
authors.initials: R
authors.lastname: Cirillo
authors.forename: M
authors.initials: M
authors.lastname: Massi
mesh_terms: D000284:Administration, Oral; D000804:Angiotensin II / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D001794:Blood Pressure / Q000187:drug effects; D001812:Blood-Brain Barrier; D002217:Carbachol / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D007093:Imidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D019808:Losartan; D008297:Male; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics; D011744:Pyrimidinones / Q000008:administration & dosage / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles / Q000008:administration & dosage / Q000493:pharmacokinetics; D013876:Thiophenes / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; C094835:LR B-081; D009539:Nicotinic Acids; D011744:Pyrimidinones; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D013876:Thiophenes; D000804:Angiotensin II; C078790:GR 117289; D002217:Carbachol; C066026:losartan carboxylic acid; D019808:Losartan